Kunihiko Tsuji
Overview
Explore the profile of Kunihiko Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
2.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39844393
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev). Methods:...
3.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al.
Cancer Med
. 2025 Jan;
14(2):e70618.
PMID: 39840727
Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable...
4.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39762722
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment. Methods: Among 449...
5.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Sci Rep
. 2025 Jan;
15(1):72.
PMID: 39747852
In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the...
6.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al.
Hepatol Res
. 2024 Nov;
PMID: 39526824
Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical...
7.
Hirano Y, Nouso K, Kariyama K, Hiraoka A, Shiota S, Wakuta A, et al.
Acta Med Okayama
. 2024 Oct;
78(5):377-386.
PMID: 39467656
We previously found that "albumin grade", formerly called the "ALBS grade," demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present...
8.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, et al.
Oncology
. 2024 Oct;
:1-13.
PMID: 39396495
Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries...
9.
Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, et al.
Liver Cancer
. 2024 Sep;
13(5):522-536.
PMID: 39296620
Introduction: The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and...
10.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1361-1373.
PMID: 39233317
Aim: This study aims to investigate the predictive factors for conversion therapy in patients with unresectable hepatocellular carcinoma (uHCC) and to evaluate the prognosis of conversion cases by comparing them...